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BACKGROUND. Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit the develop-
ment of lung tumors in experimental animals. To the authors’ knowledge there are
little data regarding whether regular use of NSAIDs reduces the risk of developing
lung carcinoma in humans.
METHODS. The association between lung carcinoma risk and regular use of NSAIDs,
including aspirin, was evaluated in a hospital-based case– control study of 1038
patients and 1002 controls.
RESULTS. The relative risk estimate of lung carcinoma associated with using
NSAIDs 3 times a week or more for 1 or more years demonstrated an odds ratio
(OR) of 0.68 (95% confidence interval [95% CI], 0.53– 0.89). Results were similar
when separated by lung histologic type. The association varied by smoking status.
The OR was1.28 (95% CI, 0.73–2.25) in never-smokers and 0.60 (95% CI 0.45– 0.80)
in ever-smokers. The smoking-specific risk estimates for aspirin were similar to
those for all NSAIDs.
CONCLUSIONS. The results of the current study suggest a possible chemoprotective
benefit with the use of NSAIDs among individuals who are former or current
smokers. Cancer 2003;97:1732– 6. © 2003 American Cancer Society.
DOI 10.1002/cncr.11242
KEYWORDS: nonsteroidal antiinflammatory drugs (NSAIDs), lung tumors, smoking
status, chemoprotective benefit.
Nonsteroidal antiinflammatory drugs (NSAIDs) are common over-the-counter drugs that have antiproliferative effects in both in
vivo and in vitro lung tumor cells.1,2 The mechanism of this action is
the inhibition of cyclooxygenase-2 (COX-2) enzymes.3,4 The COX-2
enzyme stimulates lung tumor growth by mediating prostaglandin
(PG) biosynthesis.5 In addition to lung carcinoma, a number of hu-
man tumors contain higher levels of PGs than the adjacent tissues
from which they arise. Both COX-1 and COX-2 are the rate-limiting
enzymes in the metabolism of arachidonic acid and PG synthesis.
Whereas COX-1 is constitutively expressed in most normal tissue and
is necessary for normal physiologic functions, the inducible isoform,
COX-2, is expressed in a variety of inflammatory and neoplastic
conditions. Chemoprevention clinical trials have been initiated to
determine whether selective COX-2 inhibitors affect patient re-
sponse.6
Information concerning whether NSAID use might reduce the
rate of lung carcinoma in healthy individuals is more limited. A
significant benefit was found for aspirin users who were followed for
up to 8 years after completing a baseline medication questionnaire in
the National Health and Nutrition Examination Survey I (NHNES I).7
Another cohort study, Cancer Prevention Study II (CPS II), found few
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differences in lung carcinoma mortality rates after 6
years of follow-up.8 In a California retirement commu-
nity cohort, the incidence of lung carcinoma in daily
aspirin users was reduced among women but not
among men.9 A British case– control study found a
nonsignificant reduced risk associated with frequent
aspirin prescriptions.10 With the exception of the Brit-
ish study, the relation between lung carcinoma risk
and duration of NSAID use has not been explored.
Because relatively few new cases of lung carcinoma
occurred in these cohort studies, with the exception of
CPS II, the effects of aspirin use are unclear. The
hypothesis that the risk of lung carcinoma is reduced
with regular use of NSAIDs was tested in a large case–
control study that obtained information regarding
both the frequency and duration of NSAID use.
MATERIALS AND METHODS
Several large hospitals in New York and Washington,
D.C., participated in the study between 1992 to 2000.11
Eligible subjects were identified from thoracic surgical
schedules and from oncology clinics for patients with
inoperable tumors. The diagnoses were confirmed by
review of the pathology reports. Controls were pa-
tients without cancer from the same hospital who
were identified from general admission logs. They
were matched to cases by month of interview, gender,
and age (within 5 years). For the current study, con-
trols with conditions related to regular aspirin use
were excluded from the analysis. This included con-
ditions associated with increased aspirin use including
rheumatoid arthritis (RA), osteoarthritis (OA; Interna-
tional Classification of Disease [ICD] codes 714.0 –
716.9), and joint problems (ICD code v43.6), as well as
for conditions for which NSAIDs are contraindicated
including peptic ulcer (ICD code 533) and bleeding
disorders (ICD codes 286, 7221–7229). Subjects were
interviewed by trained personnel using a structured
questionnaire that contained detailed habits on past
and current lifestyle including smoking habits, demo-
graphics, and use of over-the-counter and prescrip-
tion medications. For each medication, information
on the brand, frequency, and duration of use was
obtained. Each subject signed a consent form that was
approved by their hospital’s institutional review
board.
Statistical Analysis
All statistical analyses were performed using SAS soft-
ware (SAS Institute, Cary, NC). Regular NSAID use was
defined as use of over-the-counter aspirin or any other
NSAID (three tablets per week) for 1 or more years.
Subjects who took NSAIDs for less than 1 year or who
took them less frequently (fewer than 3 tablets per
week) were included in the reference category. The
reference group for analyses limited to aspirin only
included subjects who used neither aspirin nor
NSAIDs frequently. The odds ratio (OR) and 95% con-
fidence intervals (95% CI) were calculated for short-
term use (i.e., 12–59 months) and longer-term use.
Because controls were selected from hospitals, the use
of NSAIDs was first analyzed according to ICD diag-
nostic codes to determine the extent of possible selec-
tion bias. The use of NSAIDs among controls was
analyzed further by subject characteristics such as age,
gender, education, and smoking status to assess po-
tential confounders. Unconditional logistic regression
models were used to adjust risk estimates for known
or potential confounders such as cigarette smoking
(pack-years), age, and years of education. Analyses
were performed for all subjects and men and women
separately. The risk estimates were calculated for all
lung carcinoma cell types, and separately for adeno-
carcinoma and all other types combined. For the his-
tologic-specific analyses, each subgroup of cases was
compared with all controls in logistic regression mod-
els. Because cigarette smoking is the major cause of
lung carcinoma and it is correlated with other lifestyle
habits associated with possible lung carcinoma risk,11
separate analyses were performed among smokers.
RESULTS
The current data set included 1038 patients with lung
carcinoma and 1002 control subjects. Twenty-one
percent of controls used NSAIDs regularly. Controls
were divided into 19 different diagnostic groups based
on categories of ICD disease codes. There was little
variation in use of NSAIDs between most of these
groups (Table 1). Approximately 18% of the 28 con-
trols with circulatory system illnesses used NSAIDs.
Subjects admitted for injuries had the highest rate of
NSAID use (25%).
Among controls, there were few differences in us-
age patterns by gender, age, education, and smoking
status (Table 2). NSAIDs were taken slightly more fre-
quently by men than women and by subjects with
college degrees. Eighteen percent of current smokers,
23% of former smokers, and 20% of never smokers
used NSAIDs regularly.
Seventeen percent of cases used NSAIDs regularly.
The crude OR for lung carcinoma associated with reg-
ular NSAID use was 0.74 (95% CI, 0.59 – 0.93). In all
analyses, there were little differences between the
crude and adjusted ORs and therefore only adjusted
ORs are reported. The overall OR was 0.68 (95% CI,
0.53– 0.89; Table 3). The reduction in risk was some-
what greater for men (OR  0.61; 95% CI, 0.42– 0.87)
than for women (OR 0.82; 95% CI, 0.56 –1.20). For all
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subjects combined, there were no differences in the
risk reduction between short-term and long-term us-
ers. The OR associated with aspirin use only was 0.84
(95% CI, 0.62–1.14). The association with aspirin use
was found only in men (OR  0.70; 95% CI, 0.47–1.04)
and not in women (OR  1.11; 95% CI, 0.69 –1.80).
There was no evidence of a dose-response effect, ei-
ther when medication use was classified by duration
(12–59 months,  60 months) or by cumulative tablet
exposure.
After stratification by smoking status, regular use
of NSAIDs or aspirin was not found to be associated
with lung carcinoma risk in never-smokers (Table 4).
An inverse association was observed in ever-smokers.
When further stratified by both smoking status (never,
current, and former) and by gender, the OR for regular
use of NSAIDs was 0.37 (95% CI, 0.18 – 0.76) in male
current smokers and 1.77 (95% CI, 0.68 – 4.52) in fe-
male current smokers. In former smokers, a protective
effect was found for both men (OR  0.60; 95% CI,
0.39 – 0.94) and women (OR 0.56; 95% CI, 0.31–1.04).
Table 5 demonstates that the association with
NSAID use or aspirin did not vary substantially by lung
histologic type. The risks were similar among adeno-
carcinoma, small cell, and all other histologic types
combined.
DISCUSSION
The results of the current study showed that the risk of
lung carcinoma was reduced in smokers who regularly
used NSAIDs and that the association was consistent
for all lung histologic types. No benefit was found
among nonsmokers. The findings were similar for all
NSAIDs and for aspirin separately. These results pro-
vide what we believe to be the strongest evidence to
date for a chemoprotective effect of NSAIDs, yet the
findings from all studies are contradictory. For exam-
ple, studies of arthritic patients have not found a ben-
efit of aspirin use on lung carcinoma risk. The inci-
dence of colon carcinoma,12 but not lung carcin-
oma,12,13 was reduced among a cohort of patients with
RA. Cigarette smoking is associated with RA14,15 and
high smoking rates would offset any possible benefit
of aspirin use. A reduced incidence of both lung and
colon carcinoma was reported for OA patients,12 al-
though the protective effect against lung carcinoma
might be due to lower smoking rates among the OA
group.
The incidence rate of lung carcinoma among as-
pirin users in 12,668 adults participating in the
NHNES I was 0.68 (95% CI, 0.49 – 0.94) after 12.4 years
of follow-up.7 However, there was no information re-
garding the amount and duration of aspirin use. In the
California Leisure World cohort of 13,987 retirees, no
significant differences in lung carcinoma rates were
found by aspirin use.9 In this study, 111 cases of lung
carcinoma were found after 6.5 years of follow-up. The
relative risk was 1.35 (95% CI, 0.73, 2.321) in men and
0.29 (95% CI, 0.07, 1.14) in women. Among 635, 031
adults who were followed for 6 years in the CPS II,
there was no reduction in lung carcinoma mortality
rates among aspirin users, except for a subgroup of
women who took 1–15 tablets a month.8 Although the
1The CI was estimated by the authors based on unadjusted data. Published
relative risks are adjusted for age.
TABLE 1
Regular Use of NSAIDs among 1002 Controls by Diagnostic Categorya
Category No.(%)
Infections 12 (16.7)






BPH/other genitourinary 270 (22.2)
Skin 36 (22.2)
Muskuloskeletal 70 (24.3)
III-defined conditions 52 (19.2)
Injuries 236 (25.0)
All others 32 (18.8)
Total 214 (21.4)
NSAID: nonsteroidal antiinflammatory drugs; BPH: benign prostatic hyperplasia.
a Use of over-the-counter prescription aspirin or any other NSAID (three tablets per week) for  1 year.
TABLE 2
Regular Use of Nonsteroidal Antiinflammatory Drugs among 1002






 45 77 (20.8)
45–54 184 (23.5)
55–64 273 (19.0)
 65 468 (23.7)
Education
(yrs)
 12 126 (16.7)
12 272 (19.9)
13–15 183 (23.0)
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number of lung carcinoma deaths was not reported, a
crude estimate is approximately 1500. In a British ca-
se– control study of 2560 lung carcinoma patients,
there was no trend in risk with the number of aspirin
prescriptions in the 3 years preceding the diagnosis.10
However, among persons who had the highest num-
ber of prescriptions (7 or more), the OR was 0.84 (95%
CI, 0.69 –1.02). In the U.K., over-the-counter purchases
of pain medication are relatively uncommon because
prescription drugs are obtained without cost.
The largest discrepancy among these studies is
between the current protective findings and the lack
of an effect in the large CPS II cohort. It is possible that
the current study is biased because controls were hos-
pital patients and more likely to have been NSAID
users than the general population. This potential bias
was minimized somewhat by the inclusion of a variety
of control diagnoses. There was relatively little vari-
ability between groups. Other studies of NSAID use
and colorectal carcinoma risk that used hospital-
based controls had similar results to population-based
studies.16 Nevertheless, the use of hospital controls is
often problematic in case– control studies and bias
cannot be ruled out when interpreting the current
findings. The use of NSAIDs was not associated with a
reduced risk of lung carcinoma in female current
smokers. We did note that the percentage of NSAID
users in this subgroup was substantially lower than in
other subgroups (10.7% vs.  18%). However, whether
this finding simply reflects the variability that arises
from multiple subgroup analysis remains to be deter-
mined. Alternatively, if there is a benefit of NSAID use
TABLE 3





OR (95% CI)Cases Controls Cases Controls
NSAIDs
No/infrequent use 864 788 1.0 864 788 1.0
Regular use 174 214 0.68 (0.53–0.89) 133 130 0.84 (0.62–1.14)
No/infrequent use 864 788 1.0 864 788 1.0
12–59 mos 78 110 0.62 (0.44–0.89) 53 65 0.72 (0.47–1.11)
 60 mos 96 104 0.75 (0.53–1.06) 80 65 0.96 (0.64–1.43)
Tablets/day (yrs)a
 1 819 704 1.0 834 730 1.0
1–5 98 146 0.61 (0.45–0.83) 70 99 0.65 (0.45–0.93)
5  121 152 0.58 (0.43–0.78) 93 89 0.73 (0.51–1.05)
OR: odds ratio; NSAID: nonsteroidal antiinflammatory drugs; CI: confidence interval.
a Adjusted for age, gender, years of education, and pack-years of smoking.
TABLE 4





OR (95% CI)Cases Controls Cases Controls
Never-smokers
No/infrequent use 63 357 1.0 63 357 1.0
Regular use 21 89 1.28 (0.73–2.25) 19 51 2.03 (1.08–3.81)
Ever-smokers
No/infrequent use 801 431 1.0 801 431 1.0
Regular use 153 125 0.60 (0.45–0.80) 114 79 0.68 (0.49–0.96)
Current smokers
No/infrequent use 410 109 1.0 410 109 1.0
Regular use 72 24 0.71 (0.41–1.22) 51 16 0.72 (0.38–1.36)
Former smokers
No/infrequent use 391 322 1.0 391 322 1.0
Regular use 81 101 0.58 (0.41–0.83) 63 63 0.69 (0.46–1.04)
OR: odds ratio; NSAID: nonsteroidal antiinflammatory drug; CI: confidence interval.
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only in smokers, it is possible that an effect might have
been missed in the CPS II study because the rates were
determined for both smokers and nonsmokers com-
bined.
If the current findings do reflect a chemoprotec-
tive effect, it is uncertain why the inverse association
was limited to smokers. It is possible that smoking
might induce COX-2 expression. In 101 lung carci-
noma samples, a greater percent of COX-2 expression
was reported for smokers than for nonsmokers (32%
vs. 10%).17 Similarly, cigarette tar extracts increased
COX activity in rat pulmonary alveolar macrophages.18
Because lung carcinoma is the leading cause of cancer
deaths, the possibility that commonly used pain med-
ication can reduce the rates should be explored fur-
ther.
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